Freedom of Information request on Study synopsis and Clinical summary for Study 09 and Clinical summary for Table 4 and 5 (FOI 21/1293)
Published 31 May 2022
© Crown copyright 2022
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-20-december-2021/freedom-of-information-request-on-study-synopsis-and-clinical-summary-for-study-09-and-clinical-summary-for-table-4-and-5-foi-211293
FOI 21/1293
22nd December 2021
Dear
With regards to the below request for information, please see attached the:
- Study synopsis for Study 09
- Clinical summary Table 4
- Clinical summary Table 5
- Clinical summary for Study 09
Redactions have been made to this information, under Section 40 (Personal information), Section 41 (Information provided in confidence) and Section 43 (Commercial interests).
Section 40 and 41 are absolute exemptions and no consideration of the public interest is required. Section 43 is a qualified exemption and a consideration of the public interest should be made. We have considered the public interest and cannot see any public interest argument that outweighs the commercial harm in divulging commercial know-how/secrets to competitors that can be used to their commercial advantage. Examples of public interest arguments would be a major public health risk or a major procedural failure or irregularity.
Best regards
The FOI Licensing Team